Helix BioPharma Corp. (HBP) - Net Assets
Based on the latest financial reports, Helix BioPharma Corp. (HBP) has net assets worth CA$16.07 Million CAD (≈ $11.62 Million USD) as of October 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$19.07 Million ≈ $13.79 Million USD) and total liabilities (CA$3.00 Million ≈ $2.17 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read HBP current and long-term liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$16.07 Million |
| % of Total Assets | 84.27% |
| Annual Growth Rate | 1.13% |
| 5-Year Change | N/A |
| 10-Year Change | 392.6% |
| Growth Volatility | 110.23 |
Helix BioPharma Corp. - Net Assets Trend (2007–2025)
This chart illustrates how Helix BioPharma Corp.'s net assets have evolved over time, based on quarterly financial data. Also explore Helix BioPharma Corp. (HBP) total assets for the complete picture of this company's asset base.
Annual Net Assets for Helix BioPharma Corp. (2007–2025)
The table below shows the annual net assets of Helix BioPharma Corp. from 2007 to 2025. For live valuation and market cap data, see market value of Helix BioPharma Corp..
| Year | Net Assets | Change |
|---|---|---|
| 2025-07-31 | CA$15.59 Million ≈ $11.27 Million |
+17417.78% |
| 2024-07-31 | CA$-90.00K ≈ $-65.10K |
+89.34% |
| 2023-07-31 | CA$-844.00K ≈ $-610.54K |
-364.58% |
| 2022-07-31 | CA$319.00K ≈ $230.76K |
+122.90% |
| 2021-07-31 | CA$-1.39 Million ≈ $-1.01 Million |
-146.73% |
| 2020-07-31 | CA$2.98 Million ≈ $2.16 Million |
+190.86% |
| 2019-07-31 | CA$-3.28 Million ≈ $-2.37 Million |
-114.87% |
| 2018-07-31 | CA$-1.53 Million ≈ $-1.10 Million |
-8882.35% |
| 2017-07-31 | CA$-17.00K ≈ $-12.30K |
-100.54% |
| 2016-07-31 | CA$3.16 Million ≈ $2.29 Million |
-53.65% |
| 2015-07-31 | CA$6.83 Million ≈ $4.94 Million |
+0.23% |
| 2014-07-31 | CA$6.81 Million ≈ $4.93 Million |
+38.43% |
| 2013-07-31 | CA$4.92 Million ≈ $3.56 Million |
-20.95% |
| 2012-07-31 | CA$6.22 Million ≈ $4.50 Million |
-71.85% |
| 2011-07-31 | CA$22.11 Million ≈ $16.00 Million |
+40.30% |
| 2010-07-31 | CA$15.76 Million ≈ $11.40 Million |
-7.63% |
| 2009-07-31 | CA$17.06 Million ≈ $12.34 Million |
-16.86% |
| 2008-07-31 | CA$20.52 Million ≈ $14.85 Million |
+61.16% |
| 2007-07-31 | CA$12.73 Million ≈ $9.21 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Helix BioPharma Corp.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16414800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (July 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CA$179.29 Million | 1150.34% |
| Other Comprehensive Income | CA$3.87 Million | 24.85% |
| Other Components | CA$48.30 Million | 309.87% |
| Total Equity | CA$15.59 Million | 100.00% |
Helix BioPharma Corp. Competitors by Market Cap
The table below lists competitors of Helix BioPharma Corp. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Biosyent Inc.
V:RX
|
$116.58 Million |
|
Able Global Bhd
KLSE:7167
|
$116.60 Million |
|
Centrica PLC
LSE:CNA
|
$116.63 Million |
|
Cystech Electronics Corp
TWO:6651
|
$116.64 Million |
|
American Outdoor Brands Inc
NASDAQ:AOUT
|
$116.57 Million |
|
Dardanel Onentas Gida Sanayi AS
IS:DARDL
|
$116.57 Million |
|
Allied Tecnologia S.A
SA:ALLD3
|
$116.57 Million |
|
Faze Three Limited
NSE:FAZE3Q
|
$116.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Helix BioPharma Corp.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -90,000 to 15,586,000, a change of 15,676,000.
- Net loss of 5,205,000 reduced equity.
- Share repurchases of 2,798,000 reduced equity.
- Other comprehensive income increased equity by 3,873,000.
- Other factors increased equity by 19,806,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-5.21 Million | -33.4% |
| Share Repurchases | CA$2.80 Million | -17.95% |
| Other Comprehensive Income | CA$3.87 Million | +24.85% |
| Other Changes | CA$19.81 Million | +127.08% |
| Total Change | CA$- | % |
Book Value vs Market Value Analysis
This analysis compares Helix BioPharma Corp.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.55x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.18x to 7.55x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-07-31 | CA$1.79 | CA$2.11 | x |
| 2008-07-31 | CA$2.42 | CA$2.11 | x |
| 2009-07-31 | CA$1.64 | CA$2.11 | x |
| 2010-07-31 | CA$1.33 | CA$2.11 | x |
| 2011-07-31 | CA$1.69 | CA$2.11 | x |
| 2012-07-31 | CA$0.46 | CA$2.11 | x |
| 2013-07-31 | CA$0.37 | CA$2.11 | x |
| 2014-07-31 | CA$0.48 | CA$2.11 | x |
| 2015-07-31 | CA$0.43 | CA$2.11 | x |
| 2016-07-31 | CA$0.18 | CA$2.11 | x |
| 2017-07-31 | CA$0.00 | CA$2.11 | x |
| 2018-07-31 | CA$-0.08 | CA$2.11 | x |
| 2019-07-31 | CA$-0.15 | CA$2.11 | x |
| 2020-07-31 | CA$0.09 | CA$2.11 | x |
| 2021-07-31 | CA$-0.05 | CA$2.11 | x |
| 2022-07-31 | CA$0.01 | CA$2.11 | x |
| 2023-07-31 | CA$-0.02 | CA$2.11 | x |
| 2024-07-31 | CA$0.00 | CA$2.11 | x |
| 2025-07-31 | CA$0.28 | CA$2.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Helix BioPharma Corp. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -33.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.21x
- Recent ROE (-33.40%) is above the historical average (-184.72%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -60.26% | -224.12% | 0.24x | 1.12x | CA$-8.95 Million |
| 2008 | -33.93% | -193.93% | 0.17x | 1.06x | CA$-9.02 Million |
| 2009 | -82.65% | -367.14% | 0.20x | 1.13x | CA$-15.81 Million |
| 2010 | -91.80% | -326.32% | 0.24x | 1.15x | CA$-16.05 Million |
| 2011 | -51.32% | -250.40% | 0.19x | 1.10x | CA$-13.56 Million |
| 2012 | -280.21% | -409.39% | 0.56x | 1.22x | CA$-18.06 Million |
| 2013 | -31.91% | 0.00% | 0.00x | 1.19x | CA$-2.06 Million |
| 2014 | -127.75% | 0.00% | 0.00x | 1.15x | CA$-9.38 Million |
| 2015 | -128.07% | 0.00% | 0.00x | 1.14x | CA$-9.43 Million |
| 2016 | -306.01% | 0.00% | 0.00x | 1.41x | CA$-10.00 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-10.07 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-8.50 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-7.20 Million |
| 2020 | -376.36% | 0.00% | 0.00x | 2.05x | CA$-9.25 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-7.77 Million |
| 2022 | -1905.96% | 0.00% | 0.00x | 11.69x | CA$-6.11 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-6.21 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-9.26 Million |
| 2025 | -33.40% | 0.00% | 0.00x | 1.21x | CA$-6.76 Million |
Industry Comparison
This section compares Helix BioPharma Corp.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $30,779,914
- Average return on equity (ROE) among peers: -136.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Helix BioPharma Corp. (HBP) | CA$16.07 Million | -60.26% | 0.19x | $116.58 Million |
| Appili Therapeutics Inc (APLI) | $4.87 Million | -81.69% | 0.48x | $1.86 Million |
| Aptose Biosciences Inc (APS) | $10.57 Million | -166.31% | 1.08x | $4.36 Million |
| Arch Biopartners Inc (ARCH) | $141.48K | -593.02% | 3.59x | $20.88 Million |
| Biomind Labs Inc (BMND) | $-247.66K | 0.00% | 0.00x | $6.98 Million |
| Cybin Inc (CYBN) | $237.20 Million | -47.70% | 0.09x | $301.37 Million |
| Eupraxia Pharmaceuticals Inc (EPRX) | $5.11 Million | -84.55% | 0.14x | $393.86 Million |
| Devonian Health Group Inc (GSD) | $14.25 Million | -32.28% | 0.35x | $20.01 Million |
| Hemostemix Inc (HEM) | $4.84 Million | -81.34% | 0.10x | $8.18 Million |
| Universal Ibogaine Inc (IBO) | $295.22K | -138.30% | 0.09x | $1.13 Million |
About Helix BioPharma Corp.
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical tria… Read more